Groundbreaking Drug Launches
Orforglipron
(LY-3502970/OWL 833)
Mechanism of Action: Glucagon-like peptide-1 receptor agonists Drug class: Small molecules Originator: Chugai Pharmaceutical Indication: Obesity
Expected approval: Early 2026 Trial: ATTAIN-2
Why is Orforglipron poised to make an impact in 2026?
Obesity treatment encounters several challenges, including cost, accessibility, and patient readiness. Cost: • Treatment Costs: Obesity treatments can be costly, particularly for individuals with lower socioeconomic status. • Healthy Diet: Maintaining a healthy diet can be expensive. • Weight Loss Programs: Joining weight loss programs or gym memberships can be financially burdensome. • Medication: Many healthcare systems do not reimburse the cost of obesity medications. Access: • Access to Treatment: Some individuals may face barriers in accessing proper treatment. • Policy Changes: Changes in policies may be necessary to improve access to care.
Orforglipron poised to make an impact in 2026:
Orforglipron, Eli Lilly’s oral therapy for obesity and type 2 diabetes, is emerging as a key drug to watch in 2026. As an investigational, once-daily, non-peptide GLP-1 pill, it has demonstrated efficacy comparable to existing injectable treatments while offering the significant convenience advantage of oral administration. This positions Orforglipron as a potential game-changer in the rapidly expanding GLP-1 market. Anticipated regulatory approvals and a possible 2026 launch across both obesity and type 2 diabetes indications could enable broader patient access and accelerate market adoption.
The global weight-loss drug market is booming, growing from ~$15–26B in 2024/25 to a projected $100–190B by 2030–35, led by GLP-1 therapies
2025
2035
However, the high cost of treatments like Wegovy has limited access, with only half of U.S. patients covered by private insurance. Orforglipron’s oral form makes it more appealing for markets outside the U.S., where oral medications are preferred. Eli Lilly has licensed Orforglipron from Chugai Pharmaceutical Co., Ltd, which stands to receive tiered royalties on future worldwide sales if the product is successful. As of December 31, 2023, Chugai is also eligible for up to $140 million in regulatory milestone payments and up to $250 million in sales-based milestones if Orforglipron succeeds commercially. Lilly began phase 3 testing for Orforglipron in late 2024, with a large study involving 1,500 participants set to conclude in August 2025. According to Lilly’s third-quarter earnings, results from this trial are expected to make a significant impact on the obesity market later this year.
Regulatory milestones for Orforglipron
Registrational Trial
Eli Lilly launched the ATTAIN-2 trial to assess the safety and efficacy of orforglipron as a once-daily oral treatment for obesity and type 2 diabetes. This trial is part of a global clinical program aimed at developing orforglipron as a long-term weight management solution.
ATTAIN-2:
A phase 3, randomized, double-blind clinical trial, enrolled 1500 patients and aims to evaluate the efficacy and safety of once-daily oral orforglipron (LY3502970) compared to a placebo in adults with obesity or overweight and type 2 diabetes (NCT05872620).
“Strong ATTAIN-2 data helped orforglipron boost Lilly’s stock, easing earlier trial-related investor concerns”